NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
Top Page
NeOnc Technologies Holdings, Inc.
(NASDAQ:NTHI)
Select Model
Select Model
Rating:43Neutral
Price Target:
$5.50
▼(-38.06% Downside)
Action:ReiteratedDate:04/07/26
The score is primarily constrained by very weak financial performance (minimal revenue, large losses, accelerating cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Corporate events provide some offset via positive clinical milestones and added financing/liquidity actions, but not enough to overcome the current financial and trend risks.
Positive Factors
NEO212 Phase 1 de-risking
Establishing a Recommended Phase 2 Dose (610 mg) materially de-risks the NEO212 program: it enables a concrete Phase 2 design, regulatory engagement (Type B meeting planned), and clearer go/no-go decision points, improving the program's probability of clinical and regulatory progress.
Negative Factors
Minimal revenue vs large losses
The company's economics are characteristic of a pre-commercial biotech: negligible product revenue and outsized operating losses. This structural mismatch means value depends entirely on future clinical success and financing, raising long-term execution risk if programs stall.
Read all positive and negative factors
Positive Factors
Negative Factors
NEO212 Phase 1 de-risking
Establishing a Recommended Phase 2 Dose (610 mg) materially de-risks the NEO212 program: it enables a concrete Phase 2 design, regulatory engagement (Type B meeting planned), and clearer go/no-go decision points, improving the program's probability of clinical and regulatory progress.
Read all positive factors
NeOnc Technologies Holdings, Inc. (NTHI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$127.84M
Dividend YieldN/A
Average Volume (3M)103.40K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,806,215
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue2.84K
Enterprise Value/Gross Profit2.84K
Enterprise Value/Ebitda-1.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model
Company Description
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clin...
How the Company Makes Money
null...
NeOnc Technologies Holdings, Inc. Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| Gross Profit | 39.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| EBITDA | -59.61M | -9.10M | -12.20M | -2.85M | -3.26M |
| Net Income | -62.15M | -11.90M | -14.92M | -3.05M | -3.38M |
Balance Sheet | |||||
| Total Assets | 2.82M | 3.42M | 1.27M | 728.68K | 32.49K |
| Cash, Cash Equivalents and Short-Term Investments | 58.73K | 64.89K | 31.86K | 633.30K | 25.03K |
| Total Debt | 6.31M | 24.72K | 6.61M | 50.00K | 1.15M |
| Total Liabilities | 20.33M | 8.92M | 15.25M | 2.30M | 2.65M |
| Stockholders Equity | -17.51M | -5.50M | -13.99M | -1.58M | -2.62M |
Cash Flow | |||||
| Free Cash Flow | -20.86M | -4.21M | -1.88M | -881.74K | -396.69K |
| Operating Cash Flow | -20.36M | -4.21M | -1.88M | -881.74K | -396.69K |
| Investing Cash Flow | -500.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 20.86M | 4.25M | 1.28M | 1.49M | 250.00K |
NeOnc Technologies Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $2.62M | -0.38 | -489.66% | ― | 8.52% | 79.51% | |
46 Neutral | $42.50M | -0.71 | -80.00% | ― | ― | 9.63% | |
43 Neutral | $127.84M | -2.56 | 489.71% | ― | ― | ― | |
43 Neutral | $12.77M | -0.15 | -356.99% | ― | ― | 54.62% | |
40 Underperform | $2.71M | -0.52 | ― | ― | ― | 87.42% |
* Healthcare Sector Average
NTHI
NeOnc Technologies Holdings, Inc.
5.37
-4.63
-46.30%
GOVX
GeoVax Labs
1.18
-24.82
-95.46%
GTBP
GT Biopharma
0.40
-1.80
-81.64%
SNSE
Sensei Biotherapeutics
31.71
25.45
406.63%
CLDI
Calidi Biotherapeutics
0.25
-4.89
-95.18%
NeOnc Technologies Holdings, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
NeOnc Technologies Reports Q4 Results and Trial Progress
Neutral
Apr 3, 2026
NeOnc Technologies reported Q4 and full-year 2025 results on April 1, 2026, highlighting completion of the Phase 1 trial for NEO212 with a recommended Phase 2 dose of 610 mg and early signs of anti-tumor activity in recurrent glioblastoma and brai...
Business Operations and StrategyPrivate Placements and Financing
NeOnc Announces New Private Placement to Support Liquidity
Neutral
Mar 23, 2026
NeOnc Technologies Holdings, Inc. has been executing a series of private securities offerings since January 29, 2026, issuing common stock and five-year warrants at fixed prices of $7.20 and $9.00, respectively. The first Securities Purchase Agree...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
NeOnc Technologies Appoints New Chief Accounting Officer
Positive
Mar 17, 2026
On March 12, 2026, NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer and entered into an employment agreement granting him a $162,500 annual base salary and 170,000 restricted shares, with time-based and performanc...
Business Operations and StrategyProduct-Related Announcements
NeOnc Reports Phase 1 NEO212 Results, Sets Phase 2 Dose
Positive
Mar 6, 2026
On March 4, 2026, NeOnc Technologies reported Phase 1 dose-escalation results from its Phase 1/2 clinical trial of NEO212, its novel oral bio-conjugated therapy for recurrent glioblastoma and brain metastases. The company said the Maximum Tolerate...
Business Operations and StrategyLegal Proceedings
NeOnc Technologies Settles Fox Infused Dispute With Payment
Positive
Mar 4, 2026
On July 1, 2022, NeOnc Technologies, Inc., a subsidiary of NeOnc Technologies Holdings, Inc., entered into an Intellectual Property License and Supply Agreement with Fox Infused, LLC, under which NeOnc agreed to supply certain products and license...
Private Placements and Financing
NeOnc Technologies Completes Late-February Private Equity Offerings
Positive
Mar 4, 2026
NeOnc Technologies Holdings, Inc. completed a series of private securities offerings in early 2026, issuing common stock and five-year warrants under securities purchase agreements dated January 29 and February 24, 2026. The initial January agreem...
Business Operations and StrategyProduct-Related Announcements
NeOnc to Present Initial NEO212 Phase 1 Data
Positive
Feb 27, 2026
On February 27, 2026, NeOnc Technologies Holdings, Inc. announced it will host an investor conference call and webcast on March 4, 2026, to present initial data from the Phase 1 dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial. Th...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
NeOnc Technologies Announces Private Placement Equity Financing Deal
Positive
Jan 29, 2026
On January 29, 2026, NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to issue up to 2,222,222 shares of common stock at $7.20 per share and accompanying five-year warrants for an equal number of shares at an exercise...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.